Global landscape analysis of antibody-drug conjugate clinical trials for prostatic neoplasms: current status, opportunities and challenges.

Antibody-drug conjugates (ADCs) offer selective delivery of potent cytotoxic payloads to tumour-associated antigens and are therefore attractive candidates for biomarker-informed treatment development. However, antigen heterogeneity, payload resistance, linker stability, and on-target/off-tumour toxicities continue to complicate clinical translation. Several next-generation ADC programmes, including PSMA- and B7-H3-directed agents such as MEDI3726 and DS-7300, have reported early antitumour activity signals. At the same time, the global development landscape remains fragmented across targets, payload classes, endpoints, and sponsor types. This study therefore aimed to map the contemporary landscape of ADC clinical trials for prostatic neoplasms, clarify current development patterns, identify translational opportunities and gaps, and provide an integrated overview to support future clinical development.